Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Amadeia Rector¹, Ivana Marić², Yashaar Chaichian³, Eliza Chakravarty⁴, Miranda Cantu⁵, Michael Weisman⁶, Gary Shaw⁷, Maurice Druzin⁷ and Julia Simard¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University, Stanford, ³Stanford University, Stanford, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Global Lupus Support Group, Portage, MI, ⁶Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Stanford University School of Medicine, Palo Alto
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
Abstract Number: 0980 • ACR Convergence 2022
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Kourtney Rudzinski¹, Zaina Shahid², Yasin kanakrieh², Saloni Goyal², Kyle Shaak² and James Ross³, ¹Lehigh Valley Health Network, Tatamy, PA, ²Lehigh Valley Health Network, Allentown, PA, ³lvhn, Macungie, PA
Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…
Abstract Number: 0997 • ACR Convergence 2022
Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Aishwarya Gopal¹, Chengappa Kavadichanda², Devender Bairwa³, Molly Mary Thabah⁴ and Vir Singh Negi⁵, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁴JIPMER, Puducherry, Puducherry, India, ⁵AIIMS Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Attempts to stop glucocorticoids among Systemic Lupus Erythematosus(SLE) patients in long term remission have been successful. Continuing other immunosuppressive (IS) agents indefinitely is currently…
Abstract Number: 1141 • ACR Convergence 2022
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
Olivia Castellini-Pérez¹, Athina Spiliopoulou², Guillermo Barturen¹, Andrii Iakovliev², Manuel Martinez-Bueno¹, Elena Carnero-Montoro¹ and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology and heterogenous symptomatology which has been recently dissected using…
Abstract Number: 1352 • ACR Convergence 2022
Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
Tala El Tal¹, Avery Longmore², Abdulaziz el Mutairi¹, Amani Al Bijadi¹, Audrea Chen¹, Holly Convery¹, Dinah Finkelstein³, Linda Hiraki⁴, Chetana Kulkarni⁵, Justine Ledochowski⁶, Neely Lerman¹, Karen Leslie⁷, Deborah Levy⁸, Sharon Lorber⁹, Jayne MacMahon¹⁰, Jeanine McColl¹¹, Sarah Mossad¹², Oscar Mwizerwa¹⁰, Lawrence Ng¹², Luana Flores Pereira¹², Vandana Rawal⁷, Alaa Shehab¹, Evelyn Smith¹³, Alene Toulany¹⁴ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Department of Paediatrics, University of Toronto, ON, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Child & Youth Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Adolescent Medicine, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Factor Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Hospital for Sick Children, Division of Psychiatry, Department of Paediatrics, University of Toronto,, Toronto, ON, Canada, ¹⁴The Hospital for Sick Children, Division of Adolescent Medicine, Department of Paediatrics, University of Toronto,, Toronto, ON, Canada
Background/Purpose: Mental health (MH) problems are prevalent in adolescents with childhood-onset lupus (cSLE), with cross-sectional studies estimating prevalences of 20-60% for depression symptoms and 20-40%…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1459 • ACR Convergence 2022
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan⁵, Carolina Munoz², Maria Carmela Tartaglia⁶, Leslet Ruttan⁷, Joan Wither⁵, May Choi⁸, Nicole Anderson⁹, Dennisse Bonilla², Simone Appenzeller¹⁰, Ben Parker¹¹, Patricia Katz¹², Dorcas Beaton¹³, Robin Green⁷, Ian N. Bruce¹⁴ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Schroeder Arthritis Institute, Krembil Research Institute and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Unicamp, Campinas, São Paulo, Brazil, ¹¹Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹²UCSF, San Rafael, CA, ¹³Institute for Work & Health, Toronto, ON, Canada, ¹⁴Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Subjective cognitive impairment (SCI) is a significant problem in SLE and there are a lack of studies assessing change over time in SCI. The…
Abstract Number: 1478 • ACR Convergence 2022
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung¹, Cherie Ng¹, AMP SLE/RA consortium⁵, Michelle Petri⁶, Chandra Mohan⁷ and Chaim Putterman⁸, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Accelerating Medicines Partnership, Los Angeles, CA, ⁶Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁷University of Houston, Houston, TX, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…
Abstract Number: 1651 • ACR Convergence 2022
CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus
Georg Schett¹, Sebastian Böltz², Fabian Müller², Arnd Kleyer³, Simon Völkl², Michael Aigner², Regina Gary², Sascha Kretschmann², David Simon³, Soraya Kharboutli², Dimitrios mougiakakos⁴, Gerhard Kroenke³ and Andreas Mackensen², ¹Universitätsklinikum Erlangen, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University of Magdeburg, Magdeburg, Germany
Background/Purpose: Chimeric antigen receptor (CAR) T cells have been used to treat refractory forms of B cell and plasma cell malignancies. B cells are also…
Abstract Number: 1714 • ACR Convergence 2022
The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE
Shuichiro Nakabo¹, Donavon Sandoval-Heglund¹, Victoria Hoffmann², Mingzeng Zhang¹, Norio Hanata¹, Zerai Manna¹, Elaine Poncio¹, Sarfaraz Hasni³ and Mariana Kaplan⁴, ¹NIAMS/NIH, Bethesda, MD, ²ORS/ORF/NIH, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs including kidney and skin. While its etiology and pathogenesis are still…
Abstract Number: 1944 • ACR Convergence 2022
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
John Bridges¹, Livie Huie², Amanda Alexander³, Randy Cron², Maria Danila², Victoria Gennaro⁴, Laura Hughes², Bailey Lipham⁵, Linda McAllister⁶, Matthew Mullen⁷, Annelle Reed⁴, Daniel Reiff², Carolyn Smith⁴, Emily Smitherman², Matthew Stoll², Peter Weiser² and Melissa Mannion², ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Homewood, AL, ⁴Children's of Alabama, Birmingham, AL, ⁵University of Alabama Medical School, Birmingham, AL, ⁶Children's of Alabama, Trussville, AL, ⁷University of Alabama-Birmingham, Vestavia Hills, AL
Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
Abstract Number: 2083 • ACR Convergence 2022
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
Massimo Radin¹, Irene Cecchi², Francesca Crisafulli³, Evandro Mendes Klumb⁴, Guilherme Ramires De Jesús⁴, Miguel Ángel Saavedra⁵, Geraldine Vanessa Reyes-Navarro⁶, Luca iaccarino⁷, Maddalena Larosa⁷, Gabriella Moroni⁸, Francesco Tamborini⁹, dario Roccatello¹, Laura Andreoli³, Cecilia Beatrice Chighizola¹⁰ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of Brescia, Brescia, Italy, ⁴Instituto Fernandes Figueira, Rio De Janeiro, Brazil, ⁵Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁷University of Padova, Padova, Italy, ⁸Humanitas University, Rozzano, Italy, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁰University of Milan, Milano, Italy
Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…
Abstract Number: 2103 • ACR Convergence 2022
Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus
Sarah Lieber¹, Robyn Lipschultz¹, Syed Zahid², Myriam Lin¹, Neal Lue² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Frailty is an increasingly recognized risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Preliminary evidence is conflicting regarding whether telomere length,…
Abstract Number: 2245 • ACR Convergence 2022
Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials
Saira Sheikh¹, Caroline Donovan², Carla Menezes², Albert T. Roy², Andrew Simkus³, Diane Gross⁴, Anca Askanase⁵, Rosalind Ramsey-Goldman⁶, Vikas Majithia⁷, Nicole Wanty³, Annie McNeill³, Kristen Holtz³ and S. Sam Lim⁸, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Lupus Therapeutics, LLC, New York, NY, ³KDH Research & Communication, Atlanta, GA, ⁴Lupus Research Alliance, New York, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ⁷University of Mississippi Medical Center, Ridgeland, MS, ⁸Emory University, Atlanta, GA
Background/Purpose: To assess outcomes related to Lupus Therapeutics' Patient Advocates for Lupus Studies (LT-PALS) a peer-to-peer clinical trial (CT) education program designed to improve CT…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].